Mereo BioPharma Group plc — Company profile
Healthcare · Biotechnology · United Kingdom
Last price 0.3018 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 48.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Details
| Name | Mereo BioPharma Group plc |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 39 |
| Founded | 2015 |
| Ceo | Denise Scots-Knight |
| Country | United Kingdom |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US5894921072 |
| Cusip | 589492107 |
| Cik | 1719714 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Charles Edward Sermon | Co-Founder, General Counsel, Business Development and Company Secretary |
| Christine Fox CPA | Chief Financial Officer |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Bal Lally | Vice President and Head of Human Resources |
| Dr. Jackie Parkin | Senior Vice President and Therapeutic Head |
| Alexandra Hughes-Wilson | Chief of Patient Access and Commercial Planning |
| Bo Kara | Senior Vice President and Head of Pharmaceutical Development and CMC |
| Bharti Navsariwala | Vice President and Head of Regulatory Affairs |
Contact
| Address | One Cavendish Place, 4th Floor, London, W1G 0QF, United Kingdom |
| Phone | 44 33 3023 7300 |
| Website | https://www.mereobiopharma.com |